Cardioprotective effects of semaglutide on isolated human ventricular myocardium

URN to cite this document:: urn:nbn:de:bvb:355-epub-764478
DOI to cite this document:: 10.5283/epub.76447

Krammer, Thomas ; Baier, Maria J.

; Hegner, Philipp

; Zschiedrich, Tilman ; Lukas, David ; Wolf, Matthias ; Le Phu, Christian ; Lutz, Vanessa ; Evert, Katja

; Kozakov, Kostiantyn

; Li, Jing ; Holzamer, Andreas

; Maier, Lars S.

; Provaznik, Zdenek

; Bers, Donald M. ; Wagner, Stefan ; Mustroph, Julian

License: Creative Commons Attribution 4.0
PDF
Early View
(5MB)

Date of publication of this fulltext: 24 Mar 2025 12:50

Alternative links to fulltext:DOI Publisher

This publication is part of the DEAL contract with Wiley.

Details

Preview: Early View

Export bibliographical data

Abstract

Aims Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promising effects in reducing cardiovascular events in patients with obesity and heart failure (HF) with preserved ejection fraction (HFpEF) irrespective of concomitant diabetes. However, the exact mechanisms underlying its cardioprotective actions remain unclear. Our study investigates the direct effects of ...